Your browser doesn't support javascript.
loading
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shah, Manish A; Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Tebbutt, Niall C; Metges, Jean-Phillippe; Muro, Kei; Lee, Keun-Wook; Shen, Lin; Tjulandin, Sergei; Hays, John L; Starling, Naureen; Xu, Rui-Hua; Sturtz, Keren; Fontaine, Marilyn; Oh, Cindy; Brooks, Emily M; Xu, Bo; Li, Wei; Li, Chiang J; Borodyansky, Laura; Van Cutsem, Eric.
Affiliation
  • Shah MA; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, New York.
  • Shitara K; Department of Immunology, Nagoya University Graduate School of Medicine and Department of Gastrointestinal Oncology, National Cancer Center Hospital East and the Department of Immunology, Nagoya University Graduate School of Medicine, Tokyo, Japan.
  • Lordick F; Department of Oncology, University Cancer Center Leipzig, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Tebbutt NC; Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia.
  • Metges JP; Department of Medical Oncology, CHRU de Brest-Hopital Morvan, Arpego Network Brest, Bretagne, France.
  • Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Lee KW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
  • Tjulandin S; Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin Russian Cancer Research Centre, Moscow, Russia.
  • Hays JL; Department of Internal Medicine, The Ohio State University, James Cancer Hospital, Columbus, Ohio.
  • Starling N; Gastrointestinal Unit, The Royal Marsden, London & Surrey, United Kingdom.
  • Xu RH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Sturtz K; Western States Cancer Research NCORP, Denver, Colorado.
  • Fontaine M; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
  • Oh C; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
  • Brooks EM; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
  • Xu B; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
  • Li W; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
  • Li CJ; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Borodyansky L; 1Globe Health Institute, Boston, Massachusetts.
  • Van Cutsem E; Sumitomo Pharma Oncology, Inc., Cambridge, Massachusetts.
Clin Cancer Res ; : OF1-OF9, 2022 Jul 14.
Article in En | MEDLINE | ID: mdl-35833783
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Clin Cancer Res Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Clin Cancer Res Year: 2022 Document type: Article